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Introduction
In 2008, 33.4 million people lived with an infection by the 
human immunodeficiency virus (HIV),—which is the cause 
of the acquired immunodeficiency syndrome (AIDS), 2.7 mil-
lion got newly infected, and an estimated 2 million people were 
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Although the development of an effective vaccine is 
the main goal in the fight against AiDS, all attempts by 
numerous laboratories to develop a vaccine have failed so 
far. in addition, it is still unclear whether cytotoxic T cells or 
neutralizing antibodies or both should be induced. The major 
advantage of neutralizing antibodies is their ability to prevent 
infection and subsequent integration of the provirus into the 
cellular genome where it may persist in  form invisible to 
the immune system. Broadly neutralizing antibodies have 
been found in Hiv infected individuals, including antibodies 
directed against a highly conserved region in the membrane 
proximal external region (MPer) of the transmembrane 
envelope (TM) protein gp41 of Hiv-1. we successfully induced 
neutralizing antibodies against different gammaretroviruses 
by immunization with their respective TM proteins. These 
antibodies recognized epitopes not only in the MPer but 
also in the fusion peptide proximal region of the TM protein. 
in the case of feline leukaemia virus (FeLv), these antibodies 
protected cats from antigenemia following challenge. To 
understand the mechanism of neutralization, the interactions 
between neutralizing antibodies and their corresponding 
epitopes in the TM protein of gammaretroviruses and Hiv-1 
were analyzed. These data may help to design antigens able 
to induce specific broadly neutralizing antibodies.
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killed by AIDS, among them 300,000 children. Although the 
therapy has improved significantly in recent years, AIDS still 
cannot be cured, and the combination therapy or HAART 
(highly active antiretroviral therapy) is associated with severe 
side effects. Therefore a prophylactic vaccination is the best 
means to prevent further distribution of the HIV pandemic. 
However, all attempts to design effective vaccines have failed 
so far.
Since HIV-1, like all retroviruses, integrates its genetic 
information into the genome of the infected cells where it may 
persist undetected from the immune system, induction of neu-
tralizing antibodies preventing infection and integration seems 
to be the best vaccination strategy. Neutralizing antibodies usu-
ally interact with the surface and/or the TM proteins involved 
in the infection process and may thus prevent infection. Both 
proteins are exposed on the virus surface as trimeric envelope 
spikes (Fig. 1).
Function of the TM Protein during Infection
The structure of the envelope proteins and the mechanism of 
infection are very similar for all retroviruses (Fig. 1). The surface 
envelope protein, gp120 in the case of HIV-1 and gp70 in the case 
of gammaretroviruses, interacts with the receptor molecule(s) on 
the cell surface. The CD4 molecule and the chemokine receptors 
CXCR5 or CCR4 are the receptors for gp120 of HIV-1; different 
transporter molecules are the receptors for gp70 of gammaretrovi-
ruses.1,2 After interaction of the surface envelope proteins with the 
receptors, the glycine-rich fusion peptide at the N-terminus of the 
TM protein intercalates into the cellular membrane and confor-
mational changes in the TM protein, including an interaction of 
the C-helical and N-helical regions of the TM proteins, bring the 
membrane proximal external region (MPER) close to the fusion 
peptide proximal region (FPPR). This promotes fusion between 




www.landesbioscience.com Human vaccines 5
 review review
of the antiretroviral therapy.25,26 In addition, when 2F5 and 4E10 
were characterized, uncommon properties were observed: (1) they 
are characterized by an uncommonly long hydrophobic CDR3 
region;27,28 (2) 4E10, but not 2F5, reacts with cardiolipin.29-31 
Previously it was thought that 2F5/4E10-like antibodies are rare 
in HIV-1 infected individuals. Meanwhile, however, there is evi-
dence that such antibodies are more common.12,32-34 Most impor-
tantly, broadly neutralizing antibodies reacting with the MPER 
may recognize epitopes different from those of 2F5 and 4E10.34
Attempts to Induce Neutralizing Antibodies Specific 
for the TM Protein of HIV-1
Several novel immunogen design strategies were developed in the 
past: (1) preserving the native structure of functional Env tri-
mers or stabilization of the trimers by cross-linking; (2) unmask-
ing of epitopes; (3) stabilization of intermediated epitopes; and 
(4) using structural analogs of conserved regions such as the 
MPER (reviewed in refs. 35 and 36). All attempts to generate 
broadly neutralizing antibodies such as 2F5 and 4E10 failed.37-42 
Conformational constraints such as enhancement of the alpha-
helicity resulted in increased antigenicity, but no neutralizing 
response.39,40 Binding of 2F5 and 4E10 to their epitopes requires 
surprisingly few crucial residues in their epitope domains (LEL 
DKW ANL, the epitope of 2F5 and NWF N(D)I SNW LW, the 
epitope of 4E10, amino acid changes to produce resistance to the 
corresponding antibody occurred only in the residues shown in 
bold),43 indicating that not the sequence, but the conformation 
of epitopes is of great importance. Different reasons, why it is dif-
ficult to induce 2F5/4E10-like antibodies were discussed: (1) they 
represent autoimmune antibodies;29-31 (2) other antibodies against 
gp41 may mask the epitopes in the MPER.44 The most likely 
explanation is that it is difficult to reconstruct the conformation 
of the epitope at a particular time during the conformational 
changes of gp41 in the infection process. In addition, a strong 
interaction of different domains of the TM protein of HIV with 
lipids was observed (Fig. 1).45 When the interaction between the 
mAb 4E10 and its epitope in the lipid membrane was studied, it 
was shown that the MPER undergoes unexpected conformational 
changes upon binding of the antibody,46 showing the complexity 
and flexibility of the interaction between epitope and antibody.
Only a few publications reported immunization studies 
resulting in weakly neutralizing antibodies. For example, stable 
mimetics of the gp41 pre-hairpin intermediate were used to 
induce D5-like antibodies.38 D5 is a monoclonal reacting with 
the NHR of the pre-hairpin. The concentration of the neutral-
izing antibodies was very low. When the MPER of gp41 was 
presented in hepatitis B surface antigen (HBsAG) S1 protein 
that forms nanoparticles in the presence of lipids, no neutral-
izing antibodies were induced. However prime boost immuni-
zation with proteoliposomes containing HBsAG-MPER and the 
HIV envelope protein did raise neutralizing antibodies.47 A tri-
meric form of a chimeric protein composed of the triple stranded 
coiled-coil region from the influenza hemagglutinin subunit 2, 
HIV gp41 CHR and MPER also did not induce neutralizing 
antibodies.37 In contrast to these mostly unsuccessful attempts to 
Neutralizing Antibodies Specific  
for the TM Protein in AIDS Patients
Low amounts of neutralizing antibodies were commonly found 
in HIV-infected individuals, most of them directed against the 
SU protein.4-9 Antibodies against the TM protein are mainly 
non-neutralizing and directed against the immunodominant 
Cys-Cys loop.10,11 Usually patients develop antibodies against the 
immunodominant region (called cluster I), the C-terminal heli-
cal region (cluster II), the MPER (cluster IV), but not against 
the N-terminal region of gp41 including the fusion peptide, 
the FPPR or polar region and the N-terminal helical region.12,13 
The humoral immune response to gp41 during HIV infection is 
strong with titers up to 625-fold higher than anti-gp120 titers14 
and precedes the response against gp120.15 In addition, broadly 
neutralizing antibodies such as 2F5 and 4E10, directed at the 
MPER of gp41 (Fig. 1) and neutralizing up to 95% of all HIV 
strains, were isolated from infected individuals.16-22 Passive infu-
sion of mixtures of 2F5, 4E10 and two neutralizing antibodies 
directed at gp120, 1b12 and 2G12, into rhesus monkeys protects 
against SHIV infection. If these antibodies could be induced in 
man, a preventive HIV-1 vaccine might be possible.23,24 Also, 
these antibodies reduced the virus load in humans after cessation 
Figure 1. (A) Main functional domains of the retroviral TM protein (FP, 
fusion peptide; FPPr, fusion peptide proximal region; NHr, N-terminal 
helical region; isu, immunosuppressive domain; C-C, Cys-Cys-loop; 
CHr, C-terminal helical region; MPer, membrane proximal external 
region; MSD, membrane spanning domain). Below the membrano-
tropic domains are indicated, the darker the shade of grey, the greater 
the effect45 (1) corresponds to the FP, (2 and 3) to a part of NHr, (4) to 
the Cys-Cys-loop, (5) to the MPer and MSD, (6 to 9) are located in the 
endodomain of gp41. (B) Schematic presentation of the conformational 
changes during infection. (1) localization of the viral knob consisting of 
the surface envelope protein gp120 and the TM protein gp41 anchored 
by the MSD in the viral membrane, (2) invasion of the fusion peptide 
into the cellular membrane, prehairpin intermediate and (3) hairpin or 
six-helix-bundle formation by the CHr and NHr. (C) L caliza ion of the 
epitopes recognized by the broadly neutralizing antibodies 2F5 and 
4e10 in the MPer of gp41 of Hiv-1.
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the lentivirus HIV-1 and the gammaretrovirus PERV a limited 
sequence homology of the epitopes was observed. The epitope 
FEGWFN in p15E corresponds in localization and sequence 
to the epitope NWFN(D)IT in gp41 of HIV-1 recognized by 
the broadly neutralizing antibody 4E10 (identical amino acids 
in bold). Whereas immunizations of goats with p15E of PERV 
resulted in sera recognizing only two epitopes,48 immunization 
of rats and mice resulted in sera recognizing up to two epitopes 
in the FPPR and two additional in the MPER (designated E1a 
and E1b as well as E2a and E2b, unpublished data). The epit-
opes E2a and E2b in p15E of PERV correspond to the epitopes of 
2F5 and 4E10 in gp41 of HIV-1. Preliminary data indicate that 
only the antibodies directed against the epitopes in the MPER/
E2 region are involved in neutralization; however the function of 
the E1 region is still unclear, and we cannot exclude the presence 
of additional antibodies which do not recognize linear peptides 
used for epitope mapping.
Since there is no animal model to analyze the neutralizing 
activity of sera against the TM protein p15E of PERV, similar 
immunization studies were performed with the TM protein 
p15E of FeLV. FeLV induces leukemias and immunodeficiencies 
in cats. Immunization studies in goats, rats and cats resulted in 
strongly neutralizing antibodies and the sera recognized epit-
opes localized in the FPPR and MPER49-52 (Fig. 2). The epitope 
FEGWFN is identical in FeLV and PERV and corresponds in 
localization and sequence to the epitope NWFN(D)IT in gp41 
of HIV-1 recognized by the broadly neutralizing antibody 4E10 
(identical epitopes in bold). Despite the fact that cats carry the 
sequence of the epitopes in p15E in the form of endogenous 
feline retroviruses in their genome, cats also produce antibodies 
against these domains.51 When cats were immunized with p15E 
of FeLV and challenged with infectious virus, protection from 
induce broadly neutralizing antibodies recognizing the MPER of 
gp41 of HIV, immunization studies with the TM proteins of dif-
ferent gammaretroviruses reproducibly resulted in neutralizing 
antibodies (see below).
Successful Induction of Antibodies Neutralizing 
Gammaretroviruses by Immunization  
with their TM Protein
Corresponding immunization studies were first performed with 
the TM protein of porcine endogenous retroviruses (PERVs), 
in connection with virus safety in xenotransplantation using 
pig cells or organs. Transplantation of pig cells or organs into 
human recipients is under development to help overcome the lack 
of human donor organs. Pigs, like all mammals, carry endog-
enous retroviruses in their genome. These porcine endogenous 
retroviruses (PERVs) were shown to be released from normal 
pig cells and to infect human cells, representing a special risk 
in xenotransplantation. The development of a PERV-specific 
vaccine may help to prevent transmission of the virus to xeno-
transplant recipients. To generate such a vaccine, goats, rats and 
mice were immunized with the TM protein p15E of PERV.48 In 
all immunization studies neutralizing antibodies were obtained 
and, when the epitopes of the corresponding sera were ana-
lyzed, one epitope was found in the FPPR of p15E, designated 
E1, another in the MPER, designated E2 (Fig. 2). Surprisingly 
the localization of the epitope in the MPER was similar to the 
localization of the epitopes of 2F5 and 4E10 in the TM protein 
gp41 if HIV-1. Despite the evolutionary difference between 
Figure 2. Localization of the epitopes (black) recognized by neutral-
izing antisera induced in different species (goat, rat, mouse, cat) after 
immunization with the TM proteins p15e of Perv, FeLv and Korv. The 
fusion peptide and the membrane spanning domain are not shown.
Figure 3. Domains in the FPPr and MPer interacting with each other 
and with the monoclonal antibodies 2F5 and 4e10. (1 and 5) represent 
the sequence env512-552 in the FPPr, (6) is the sequence env656-681 
in the MPer. (1) a synthetic peptide corresponding to the underlined 
sequence, enhances the binding of 2F5 to the peptide NeQ eLL eLD 
KwA SLw containing the epitope of 2F5 (the epitope is underlined),54,55 
(2) the underlined sequence was reported to be recognized by 4e10 
with the boxed sequence as core epitope,59 (3) the underlined sequence 
enhances binding of 2F5 to its epitope,60 (4) the underlined sequence 
was found to interact with the FPPr,56 (5) a peptide corresponding 
to the underlined sequence supports formation of a stable six-helix 
bundle when added to the NHr peptide number (6) and (6) sequence 
env656-681, a peptide corresponding to the underlined sequence sup-
ports formation of a stable six-helix bundle when added to the peptide 
number (5), the epitopes of 2F5 and 4e10 are boxed.57
©2011 Landes Bioscience.
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during infection of HIV-1.56-58 (Fig. 3) It should be mentioned 
that, besides the interaction between 4E10 and 2F5 and their
epitopes in the MPER, binding of both antibodies to regions in 
the FPPR have been reported,59,60 although not distinctly char-
acterized. Interestingly, no interaction was found by SPR analy-
sis between peptides corresponding to the E1 domain and the 
E2 domain in the MPER of p15E of PERV (unpublished data).
False Positive Results in Neutralization Assays
The problem of false positive results in neutralization assays is a 
still largely underestimated topic. Analyses of sera from animals 
immunized with TM proteins of different gammaretroviruses as 
well as with gp41-derived proteins or peptides often show false 
positive results. False positive results were also observed when 
preimmune sera were analyzed. Isolation of the immunoglobu-
lins sometimes, but not always, eliminated the false positive 
effect. There are only speculations on how such false positive 
effects may be generated. For example, uncompleted coagula-
tion processes, opsonizing antibodies, cross-reacting antibodies, 
cytokines induced by infections of the immunized animals with 
other microorganisms may cause inhibition of virus infection in 
neutralization assays. The influence of endotoxin on the results 
of neutralization assays was well studied.61 Endotoxin in the form 
of lipopolysaccharides may be released into sera by contaminat-
ing bacteria and can induce beta-chemokines in blood cell-based 
neutralization assays inhibiting HIV-1 infection as shown by.61 In 
addition, interferon gamma released from blood cells after inter-
action with endotoxin may give false positive results in TZM-bl 
cell-based neutralizing assays. Therefore, preparation, handling, 
transport, freeze-thawing and storage of preimmune and immune 
sera are of great importance when their neutralizing activity is 
investigated. As mentioned above, in some cases the use of puri-
fied immunoglobulins in neutralization assays together with epi-
tope mapping confirming the binding to the TM protein may 
prove the specificity of the neutralizing antibodies. Neutralizing 
antibodies should be thoroughly characterized using strong crite-
ria (Table 1).
Influence of the Immunosuppressive Domain
The immunosuppressive (isu) domain of the TM proteins of 
retroviruses is located in the C-terminal part of the N-terminal 
helical region of the protein (Fig. 1). The isu domain is highly 
conserved among all retroviruses, and peptides corresponding 
to this domain were shown to inhibit lymphocyte prolifera-
tion, to modulate cytokine release from normal peripheral blood 
mononuclear cells (PBMCs) and to modulate gene expression in 
normal PBMCs (reviewed in refs. 62–66). Mutations in the isu 
domain abrogated the immunosuppressive activity of the TM 
proteins, and immunization with TM proteins containing the 
mutated isu domain resulted in increased antibody responses 
(reviewed in refs. 67 and 68, and our own results), indicating 
that the isu domain should be inactivated in order to achieve an 
effective immunization against retroviral TM proteins.
antigenemia was observed in three out of six immunized cats 
(50%), whereas all three non-immunized cats got infected and 
died from leukemia.50 These data indicate that immunization 
with the TM protein of a retrovirus induces protective immunity. 
In parallel, cats were immunized with the recombinant surface 
envelope protein gp70 of FeLV (which is the commercial vac-
cine Leucogen). Immunized with gp70, all cats were protected. 
Moreover, when cats were immunized with a combination of 
gp70 and p15E, higher titres of neutralizing antibodies were 
observed (unpublished data). The same results were obtained 
when rats were immunized simultaneously with gp70 and p15E 
of FeLV52 or PERV (unpublished data). In addition, when goats, 
rats and mice were immunized with p15E of the KoRV, neutraliz-
ing antibodies were induced53 and similar epitopes were observed 
as in the case of FeLV and PERV (unpublished data).
Interaction between the MPER and FPPR
When the epitopes of the monoclonal antibodies 2F5 and 4E10 
were mapped, using the same method as used for the epitope 
mapping of goat, rat, cat and mice sera after immunization with 
the TM proteins of different gammaretroviruses such as PERV, 
FeLV and KoRV, only one epitope was recognized by each mono-
clonal antibody which was localized in the MPER.54 In order 
to analyze whether a domain in the FPPR may be involved in 
the mechanism of neutralization by 2F5 and 4E10, overlapping 
peptides corresponding to the entire surface envelope protein 
gp120 and the TM protein gp41 of HIV-1 were used in order to 
study which of these peptides enhance the binding of 2F5 and 
4E10 to a peptide containing their epitopes. One peptide was 
identified, enhancing the binding of 2F5 and 4E10 to their epi-
topes, located in the FPPR just opposite the MPER54,55 (Fig. 1). 
Although neither 2F5 nor 4E10 did bind to this FPPR-derived 
peptide, the presence of this peptide increased binding of the 
antibodies to their epitopes three to four times, indicating that 
interaction between the FPPR-derived and the MPER-derived 
peptides results in a conformation allowing better binding of 2F5 
or 4E10. A direct interaction between the FPPR-derived and the 
MPER-derived peptides was confirmed by surface plasmon reso-
nance (SPR).54 This interaction suggests that, for the induction 
of neutralizing antibodies of the type 2F5/4E10, simultaneous 
use of both domains may be essential.55 Meanwhile, other pub-
lications also support the interaction of domains in the FPPR 
and the MPER during the conformational changes occurring 
Table 1. Criteria for the characterization of neutralizing antibodies
Neutralizing in two different neutralization assays, e.g., based on 
measurement of provirus integration by real time PCr and TZM-bl cell 
based assay
Neutralizing activity is dose-dependent and can be diluted out
Neutralizing antibodies bind to the antigen used for immunization in 
western blot assays, eLiSA or immunoprecipitation
epitope was identified
Neutralizing activity confirmed in an independent laboratory
©2011 Landes Bioscience.
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performed. Only if these complex conformations are character-
ized, corresponding antigens can be designed and neutralizing 
antibodies preventing retroviral infections including infections 
with HIV-1 can be induced.
Acknowledgements
I would like to thank Mrs. B. Brandi and Dr. V. Morozov for 
critical reading of the manuscript.
Outlook
Retroviral TM proteins undergo complex conformational 
changes during the infection process (Fig. 1). Intermediated 
structures, which are short-lived, may represent the required 
targets for neutralizing antibodies. To gain insight into antige-
nicity, immunogenicity and function of different domains of 
the TM proteins during infection, additional studies should be 
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